by Elena Iemma | Nov 30, 2021 | News
PROVIDENCE, RI, November 30, 2021 /PRNewswire/ — Today EpiVax, Inc. (“EpiVax”) confirmed that the company’s EPV-CoV-19 vaccine epitope sequences are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc....
by Elena Iemma | May 17, 2021 | News
PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies...
by Adam | Jul 24, 2020 | News
Are we “Checking the Box” or Making Vaccines that work? We need a COVID-19 vaccine! From China to the US to Europe and even Africa, scientists are working tirelessly, if not at “warp speed”, to develop and test more than one COVID-19...
by Adam | Apr 9, 2020 | News
Read the original BusinessWire publication here. ROCKVILLE, MD, PROVIDENCE, RI, and GOLDEN, CO, April 09, 2020 — Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms,...
by Adam | Mar 24, 2020 | News
March 24, 2020 Niel, Belgium: eTheRNA Immunotherapies nv (‘eTheRNA’ or ‘The Company’), a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform, today announced that a consortium has been formed with North American and...
